Skip to main content

Talimogene laherparepvec Disease Interactions

There are 4 disease interactions with talimogene laherparepvec.

Major

Talimogene laherparepvec (applies to talimogene laherparepvec) immunocompromised

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Talimogene laherparepvec is a live, attenuated herpes simplex virus. The use talimogene laherparepvec is contraindicated in patients who are immunocompromised as its administration in these patients may cause life-threatening disseminated herpetic infection.

References (1)
  1. (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Major

Talimogene laherparepvec (applies to talimogene laherparepvec) immunodeficiency

Major Potential Hazard, Moderate plausibility. Applicable conditions: Lymphoma, Leukemia

Do not administer talimogene laherparepvec to patients with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.

References (1)
  1. (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Moderate

Talimogene laherparepvec (applies to talimogene laherparepvec) autoimmune disorders

Moderate Potential Hazard, Moderate plausibility.

The use of talimogene laherparepvec may result in immune-mediated events. Exercise care when using this agent in patients with underlying autoimmune disease or before continuing treatment in those patients that have developed immune-mediated events. Close monitoring is recommended.

References (1)
  1. (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Moderate

Talimogene laherparepvec (applies to talimogene laherparepvec) multiple myeloma

Moderate Potential Hazard, Moderate plausibility.

Plasmacytoma, in proximity to the injection site, has been reported after administration of talimogene laherparepvec in a patient with smoldering multiple myeloma. It is recommended to consider the risks and benefits of treatment in patients with multiple myeloma or in whom plasmacytoma develops during treatment. Close monitoring is recommended.

References (1)
  1. (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA

Switch to consumer interaction data

Talimogene laherparepvec drug interactions

There are 299 drug interactions with talimogene laherparepvec.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer